May Ibrutinib Have Activity in Respiratory Complications by SARS-CoV-2? Clinical Experience in a Patient with Chronic Lymphocytic Leukemia

COVID-19 is affecting many countries all around the world. Unfortunately, no treatment has already been approved for the management of patients infected by SARS-CoV-2. It seems that SARS-CoV-2 can induce the activation of an exaggerated immune response against itself according to different mechanism...

Descripción completa

Detalles Bibliográficos
Autores principales: Molina-Cerrillo, Javier, Marquet-Palomanes, Juan, Alonso-Gordoa, Teresa, López-Jiménez, Javier, Grande, Enrique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830068/
https://www.ncbi.nlm.nih.gov/pubmed/33467441
http://dx.doi.org/10.3390/healthcare9010078

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830068/
https://www.ncbi.nlm.nih.gov/pubmed/33467441
http://dx.doi.org/10.3390/healthcare9010078

Ejemplares similares